Evidence map›Paper›PMID 39651421›Full record

ReviewClinical Medicine Insights. Oncology2024

Role of Bispecific Antibodies in Gastroenteropancreatic Neuroendocrine Neoplasms (GEP-NENs): Review of Literature.

Amr Mohamed, Mai Elhawi, Marcus Trybula, Mohamed Elshawy, Sakti Chakrabarti, Eva Selfridge, Sylvia L Asa

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Clinical Medicine Insights. Oncology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Amr MohamedDivision of Medical Oncology, Department of Medicine, University Hospitals, Seidman Cancer Center, Case Western Reserve University, Cleveland, OH, USA.ORCID https://orcid.org/0000-0002-6962-3535
Mai ElhawiDepartment of Clinical Oncology, Ain Shams University Hospital, Cairo, Egypt.
Marcus TrybulaDivision of Medical Oncology, Department of Medicine, University Hospitals, Seidman Cancer Center, Case Western Reserve University, Cleveland, OH, USA.
Mohamed ElshawyDepartment of Surgery, Cleveland Clinic Foundation, Cleveland, OH, USA.
Sakti ChakrabartiDivision of Medical Oncology, Department of Medicine, University Hospitals, Seidman Cancer Center, Case Western Reserve University, Cleveland, OH, USA.
Eva SelfridgeDivision of Medical Oncology, Department of Medicine, University Hospitals, Seidman Cancer Center, Case Western Reserve University, Cleveland, OH, USA.
Sylvia L AsaDepartment of Pathology, University Hospitals, Seidman Cancer Center, Case Western Reserve University, Cleveland, OH, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Gastroenteropancreatic neuroendocrine neoplasms (GEP-NENs) are a heterogeneous group of neoplasms with an increasing incidence in the last few decades. Despite therapeutic advances in the management of GEP-NENs, resistance to many of these treatments has made their management a great challenge. One of the most recent advances in oncologic therapy is targeting multiple receptors simultaneously and engaging immune cells in the tumor microenvironment through bispecific antibodies (BsAbs). Since the FDA approval of the anti-CD3 × anti CD19 BsAb blinatumomab, for management of B-cell acute lymphoblastic leukemia, around a hundred different BsAbs have been developed and tested in various clinical trials. In this article, we review the current development of BsAbs developed or being currently tested for the management of GEP-NENs, their mechanism of action, current results from ongoing trials, toxicities, and upcoming trials.

Indexed as

bispecific antibodiesGastroenteropancreatic neuroendocrine tumors

Identifiers

PMID39651421
PMCPMC11624570

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.